BIOR vs. NNVC, LSTA, ONCT, UBX, BCTX, BFRG, APRE, CPIX, ENLV, and ITRM
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include NanoViricides (NNVC), Lisata Therapeutics (LSTA), Oncternal Therapeutics (ONCT), Unity Biotechnology (UBX), BriaCell Therapeutics (BCTX), Bullfrog AI (BFRG), Aprea Therapeutics (APRE), Cumberland Pharmaceuticals (CPIX), Enlivex Therapeutics (ENLV), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical preparations" industry.
Biora Therapeutics (NASDAQ:BIOR) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
In the previous week, NanoViricides had 1 more articles in the media than Biora Therapeutics. MarketBeat recorded 4 mentions for NanoViricides and 3 mentions for Biora Therapeutics. Biora Therapeutics' average media sentiment score of 1.15 beat NanoViricides' score of 0.80 indicating that Biora Therapeutics is being referred to more favorably in the media.
Biora Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.
Biora Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 2,426.95%. Given Biora Therapeutics' higher probable upside, analysts plainly believe Biora Therapeutics is more favorable than NanoViricides.
Biora Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
43.7% of Biora Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 51.0% of Biora Therapeutics shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NanoViricides is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biora Therapeutics received 5 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 71.43% of users gave Biora Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
Summary
Biora Therapeutics beats NanoViricides on 10 of the 14 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
